Grass pollen allergoids(Allergopharma GmbH & Co. KG)(Grass pollen allergoids(Allergopharma GmbH & Co. KG))

概要

基本信息

药物类型

变应原提取物

别名

Allergovit 6 Grasses、Grass pollen allergoids

靶点-

作用机制

免疫调节剂

治疗领域

免疫系统疾病

在研适应症

过敏超敏反应

非在研适应症

过敏性鼻结膜炎季节性过敏性鼻炎

原研机构

Allergopharma GmbH & Co. KG

在研机构

Allergopharma GmbH & Co. KG

非在研机构-

最高研发阶段批准上市

首次获批日期

荷兰 (2013-06-11),

过敏

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

6

项与 Grass pollen allergoids(Allergopharma GmbH & Co. KG) 相关的临床试验

NCT04104828 / CompletedN/AIIT

Comparison of Innate Immune Responses Induced by Allergy Immunotherapy (AIT) With Different Adjuvants

The primary objective of the pilot study is to compare inflammatory responses in blood sera from patients receiving first allergen immunotherapy (AIT) with aluminium (Alum), microcrystalline tyrosine (MCT), or a combination of MCT and monophosphoryl lipid A (MPLA) as adjuvants. The AIT products are containing allergen extracts of grass and tree pollen). Blood is collected before as wells as one day, seven days, and 6-7 weeks after first AIT, and the blood is analysed for content of inflammatory proteins and antibodies.

开始日期2019-11-05

申办/合作机构

University of Zurich

NCT02297490 / Terminated临床2期

Evaluation of the Utility of an Environmental Exposure Chamber (EEC) for Assessing Efficacy of Specific Immunotherapy (SIT) in Pivotal Clinical Trials

The study will explore how allergy symptoms experienced during the grass pollen season compare to symptoms experienced in the Environmental Exposure Chamber (EEC).
There are 2 treatments in this study. Both treatments are injected under the skin. Allergovit® Grasses works by helping the body's immune system get used to grass-pollen before the grass pollen season begins which may lead to decreased sensitivity and reduced allergy symptoms during the grass season. Placebo treatment does not contain grass pollen mixture, and is not expected to reduce allergic symptoms overtime.

开始日期2014-01-01

申办/合作机构

Allergopharma GmbH & Co. KG

[+1]

NCT00841256 / Completed临床3期

... Study to Evaluate Efficacy and Safety of Perennial Sublingual SIT With a Solution of Grass Pollen Allergen ... in Children With Clinically Relevant Grass Pollen Sensitivity in Comparison to a ... Standard Treatment With Add on Placebo

Evaluation of safety and efficacy of sublingual immunotherapy with grass pollen allergens formulated as solution in comparison to a symptomatic standard treatment with add on placebo in grass pollen allergic children suffering from allergic rhinitis/rhinoconjunctivitis with or without bronchial asthma.

开始日期2008-02-01

申办/合作机构

Allergopharma GmbH & Co. KG

100 项与 Grass pollen allergoids(Allergopharma GmbH & Co. KG) 相关的临床结果

登录后查看更多信息

100 项与 Grass pollen allergoids(Allergopharma GmbH & Co. KG) 相关的转化医学

登录后查看更多信息

100 项与 Grass pollen allergoids(Allergopharma GmbH & Co. KG) 相关的专利（医药）

登录后查看更多信息

2

项与 Grass pollen allergoids(Allergopharma GmbH & Co. KG) 相关的文献（医药）

1990-01-01·Journal of Allergy and Clinical Immunology1区 · 医学

Frequency of booster injections of allergoids

1区 · 医学

Article

作者: Peter S. Creticos ; David G. Marsh ; Philip S. Norman

In 1982, 43 ragweed-sensitive patients receiving maintenance injections of full doses of ragweed allergoid were selected for a study of the immunologic and clinical efficacy of booster injections only four times a year. These patients had participated for 2 to 7 years as part of a trial of mixes of up to four allergoids to common pollens in the mid-Atlantic area tailored to each patient's skin test sensitivity. They were divided into a group (21 patients) to receive injections every 3 months and a group (22 patients) to receive injections about every 6 weeks (eight injections per year). Patients were rerandomized after 1 year so that half of each original group switched to the alternate treatment, and this program was continued until after the ragweed season of 1985. Thirty-four patients were still under study the last year. Doses, per injection, were 100 allergoid units (1 allergoid unit equals 100 PNU) of each allergen in the mixture. Symptom scores during the 8 weeks of each of the four ragweed seasons were not significantly higher in the 3-month treated group. IgG antibody levels to Amb a I (antigen E) were followed until early 1984 and were not significantly different in the two groups, even though the 6-week treated patients received a two times higher cumulative dose per year. Rates of local and systemic reactions (percent of injections eliciting reactions) were not different in the groups, which means that the 3-month treated group had about half as many reactions by virtue of taking half as many injections.(ABSTRACT TRUNCATED AT 250 WORDS)

1970-05-01·Immunology

Studies on "allergoids" prepared from naturally occurring allergens. I. Assay of allergenicity and antigenicity of formalinized rye group I component.

Article

作者: Lichtenstein, L M ; Campbell, D H ; Marsh, D G

100 项与 Grass pollen allergoids(Allergopharma GmbH & Co. KG) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	V01AA02	-

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
过敏	荷兰	Allergopharma GmbH & Co. KG	2013-06-11
超敏反应	-	Allergopharma GmbH & Co. KG	-

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
过敏性鼻结膜炎	临床1期	德国	Allergopharma GmbH & Co. KG	2004-01-01
过敏	临床1期	德国	Allergopharma GmbH & Co. KG	2004-01-01
季节性过敏性鼻炎	药物发现	德国	Allergopharma GmbH & Co. KG	2015-10-29